Search Within

Lisa Bodei

Formats
  1. Meeting Abstract (69)
  2. Journal Article (62)
  3. Review (34)
  4. Book Section (18)
  5. Editorial (12)
  6. Guidelines (9)
  7. Conference Paper (2)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Molecular Imaging and Therapy Service (210)
  2. Radiology, Department of (210)
  3. Sloan Kettering Institute Postdocs (210)
  4. Center for Pancreatic Cancer Research (35)
  5. Department of Medicine (33)
  6. Solid Tumor Oncology Division (31)

More Groups

People
  1. Heiko Schoder (20)
  2. Jason Lewis (18)
  3. Diane Reidy (17)
  4. Joseph O'Donoghue (13)
  5. Simone Krebs (11)
  6. Michael Morris (10)

More People

Years
  1. 2025 (7)
  2. 2024 (15)
  3. 2023 (26)
  4. 2022 (16)
  5. 2021 (27)
  6. 2020 (31)

More Years

Publications
  1. Journal of Nuclear Medicine (36)
  2. Neuroendocrinology (32)
  3. European Journal of Nuclear Medicine and Molecular Imaging (26)
  4. Pancreas (16)
  5. Journal of Clinical Oncology (15)
  6. Radiopharmaceutical Therapy (9)

More Publications

Publishers
  1. Springer (48)
  2. Society of Nuclear Medicine (36)
  3. S. Karger AG (32)
  4. Lippincott Williams & Wilkins (22)
  5. American Society of Clinical Oncology (15)
  6. Elsevier Inc. (11)

More Publishers

Results (210)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ACR-ACNM-ASTRO-SNMMI practice parameter for Lutetium-177 (Lu-177) DOTATATE therapy
    Guidelines

    Love, C.; Desai, N. B.; Abraham, T.; Banks, K. P.; Bodei, L.; Boike, T.; Brown, R. K. J.; Bushnell, D. L.; DeBlanche, L. E.; Dominello, M. M.; more...
    Clinical Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Peptide receptor radionuclide therapy with 177lutethium or 90Yttrium-DOTA-TATE or -TOC in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): Results from a single institutional retrospective analysis
    Meeting Abstract

    Rubino, M.; Di Stasio, G. D.; Spada, F.; Rocca, P. A.; Laffi, A.; Fazio, N.; Bodei, L.; Grana, C. M.
    Journal of Neuroendocrinology (2022)

    Fulltext@MSK | Save
  • ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
    Review

    Hicks, R. J.; Dromain, C.; de Herder, W. W.; Costa, F. P.; Deroose, C. M.; Frilling, A.; Koumarianou, A.; Krenning, E. P.; Raymond, E.; Bodei, L.; more...
    Journal of Neuroendocrinology (2022)

    Fulltext@MSK | Save
  • EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds
    Guidelines

    Weber, M.; Lam, M.; Chiesa, C.; Konijnenberg, M.; Cremonesi, M.; Flamen, P.; Gnesin, S.; Bodei, L.; Kracmerova, T.; Luster, M.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2022)

    Fulltext@MSK | Save
  • The phase 3 NETTER-1 study of [(177)Lu-]Lu-DOTA-TATE in patients with midgut neuroendocrine tumours: Final overall survival and long-term renal safety
    Meeting Abstract

    Kunz, P.; Caplin, M. E.; Ruszniewski, P. B.; Bodei, L.; Hendifar, A.; Mittra, E.; Wolin, E. M.; Yao, J. C.; Pavel, M. E.; Grande, E.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, R. K. G.; Krebs, S.; Reidy, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schoder, H.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
    Journal Article

    Strosberg, J. R.; Caplin, M. E.; Kunz, P. L.; Ruszniewski, P. B.; Bodei, L.; Hendifar, A.; Mittra, E.; Wolin, E. M.; Yao, J. C.; Pavel, M. E.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors
    Meeting Abstract

    Strosberg, J. R.; Caplin, M. E.; Kunz, P. L.; Ruszniewski, P. B.; Bodei, L.; Hendifar, A. E.; Mittra, E.; Wolin, E. M.; Yao, J. C.; Pavel, M. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility
    Journal Article

    Modlin, I. M.; Kidd, M.; Falconi, M.; Filosso, P. L.; Frilling, A.; Malczewska, A.; Toumpanakis, C.; Valk, G.; Pacak, K.; Bodei, L.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Somatostatin receptor imaging and theranostics: Current practice and future prospects
    Review

    Park, S.; Parihar, A. S.; Bodei, L.; Hope, T. A.; Mallak, N.; Millo, C.; Prasad, K.; Wilson, D.; Zukotynski, K.; Mittra, E.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save